Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 8th 2016

Researchers Develop Model to Predict Chemotherapy Success in Aggressive Breast Cancer

Christina Mattina

At the 2016 San Antonio Breast Cancer Symposium, researchers announced the creation of a model to identify patients with triple negative breast cancer who are most likely to respond to chemotherapy.

December 8th 2016

Integrating Palliative Care Into Outpatient Oncology: A Case Study

Karen Mulvihill, DNP, APRN, FNP-BC, ACHPN

This article examines the integration of palliative care in a community cancer center-an example of how one program integrated palliative care.

December 7th 2016

ASCO Makes Recommendations to Reduce Cardiac Risk in Survivors of Adult-Onset Cancers

Surabhi Dangi-Garimella, PhD

A panel of 21 expert clinicians from the field conducted a systematic review of meta-analyses randomized clinical trials, observational studies, and clinical experience, to develop recommendations that have been published in the Journal of Clinical Oncology.

December 6th 2016

CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

December 5th 2016

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

Surabhi Dangi-Garimella, PhD

Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.

December 5th 2016

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy

Immuno-oncology will be an important part of cancer care in the future, but probably not the only part, predicted Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network. He also explained how patient advocacy and an enduring healthcare system are essential to the advancement of cancer care.

December 5th 2016

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

December 5th 2016

Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.

December 4th 2016

ASH Symposium on Quality Addresses Health IT Challenges for the Provider and the Patient

Surabhi Dangi-Garimella, PhD

The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.

December 4th 2016

Phase 3 LyMa Trial: Rituximab After ASCT Improves OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

December 4th 2016

Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams

Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

December 4th 2016

Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients

A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.

December 3rd 2016

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

Surabhi Dangi-Garimella, PhD

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.

December 3rd 2016

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

Surabhi Dangi-Garimella, PhD

Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

December 3rd 2016

David Fabrizio Says Surrogate Endpoints Will Help Accelerate Drug Discovery

Surrogate endpoints, or endpoints other than overall survival, will help accelerate drug discovery and provide additional solutions for patients, according to David Fabrizio, of Foundation Medicine, Inc. However, alternate endpoints are not without their drawbacks.

December 3rd 2016

Dr David Porter Compares Use of CAR T-Cells for B-Cell and Solid Tumors

Chimeric antigen receptor (CAR) T-cells have been dramatically effective in treating B-cell cancers, according to David L. Porter, MD, of the University of Pennsylvania Health System. He also identified the use of CAR T-cells for treating solid tumors as a research area that will see more development in the coming years.

December 2nd 2016

NICE Recommends Pembrolizumab for Advanced Lung Cancer Following Additional Price Cut

AJMC Staff

NICE recommends pembrolizumab for use in advanced lung cancer following additional data review and a further discount in price.

December 2nd 2016

Genomic Changes Ensure Chemotherapy Response in Testicular Cancer

Surabhi Dangi-Garimella, PhD

Research from the Dana-Farber Cancer Institute and the Broad Institute, published in Nature, has identified genomic changes that could explain the development of testicular cancer and why this disease is more responsive to chemotherapy.

December 2nd 2016

This Week in Managed Care: December 2, 2016

This week, the top stories in managed care included the president-elect's picks for HHS and CMS, the American Diabetes Association addressed psychosocial care for patients with diabetes, and the American Society of Clinical Oncology released criteria on creating clinical pathways.

December 1st 2016

Precision CAR-T Trial Shows Early Signs of Success in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.

November 30th 2016

Statins Could Reduce Mortality in Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.

November 30th 2016

House Committee to Scrutinize the Working of USPSTF

Surabhi Dangi-Garimella, PhD

The House Energy and Commerce Committee's subcommittee on health will gather testimonial from leaders of the US Preventive Services Task Force, the American Academy of Family Physicians, and the American Urologic Association, on a bill called H.R. 1151.

November 30th 2016

Dr Leonard Fromer Discusses Precision Medicine in Oncology

Cancer patients can now receive individually personalized treatment thanks to algorithms that account for their own unique factors, according to Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.

November 29th 2016

Hospitalization a Major Burden on Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD

A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket costs averaged at 23.7% of their household income. A majority of these costs could be attributed to hospitalization.

November 29th 2016

ASCO Framework Can Help Providers Assess Clinical Pathway Programs

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology (ASCO) has released the Criteria for High-Quality Clinical Pathways in Oncology, which is expected to help providers assess the quality, utility, and integrity of pathway programs in the United States.

November 29th 2016

What We're Reading: Warren Says Pharma "Hijacked" Cures Bill

AJMC Staff

What we're reading, November 29, 2016: Warren cries foul over pharma's role in legislation; women fear what will happen to coverage under Trump; and Gallup poll finds most Americans want changes or repeal of the Affordable Care Act.

November 28th 2016

21st Century Cures Set for a Midweek House Vote

Surabhi Dangi-Garimella, PhD

With $372 million carved out for the National Institutes of Health innovation account in 2017, and about $114 million assigned to President Barack Obama’s Precision Medicine Initiative for the fiscal year 2018, the 21st Century Cures Act has a lot at stake for healthcare in the United States.

November 26th 2016

Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology

Oncology is a perfect fit for the bundled payment model, because it evaluates the outcomes, patient satisfaction, and cost of an oncology episode, said Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ. She said that Horizon adopted the bundled payment model early to cope with New Jersey’s rising healthcare costs.

November 26th 2016

Mitigating Chemotherapy-Induced Neutropenia With a Novel Same-Day Treatment

AJMC Staff

Trial data on the use of plinabulin for mitigating chemotherapy-induced neutropenia with docetaxel will be presented as a poster at the American Society of Hematology’s annual meeting in San Diego.

November 25th 2016

Risk Factors for Neutropenia and Infections in Childhood ALL

AJMC Staff

A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.

...

86 87 88 89 90 91 92 93 94

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions